## Lingshu Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9853470/publications.pdf

Version: 2024-02-01

26 6,741 20 25 papers citations h-index g-index

36 36 36 10241 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell, 2022, 185, 113-130.e15.	13.5	64
2	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 2022, 386, 1088-1091.	13.9	338
3	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell, 2022, 185, 1556-1571.e18.	13.5	179
4	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science, 2022, 376, eabn8897.	6.0	119
5	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	2.9	287
6	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. Structure, 2022, 30, 1233-1244.e7.	1.6	13
7	Broadly neutralizing antibodies target the coronavirus fusion peptide. Science, 2022, 377, 728-735.	6.0	111
8	Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients. Frontiers in Immunology, 2021, 12, 615102.	2.2	15
9	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science Translational Medicine, 2021, 13, .	5.8	347
10	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity, 2021, 54, 769-780.e6.	6.6	37
11	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. Frontiers in Immunology, 2021, 12, 662909.	2.2	O
12	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373,	6.0	174
13	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj5413.	5.8	79
14	Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science, 2021, 373, 1372-1377.	6.0	459
15	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299.	6.0	244
16	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. Journal of Biological Chemistry, 2021, 297, 101127.	1.6	9
17	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates. Science, 2021, 374, 1343-1353.	6.0	83
18	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153

#	Article	IF	CITATION
19	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports, 2020, 33, 108322.	2.9	59
20	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	13.9	936
21	Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation. Cell Reports, 2020, 32, 108088.	2.9	13
22	Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor. Cell Host and Microbe, 2020, 28, 434-444.e4.	5.1	16
23	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7348-E7357.	3.3	944
24	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell, 2016, 166, 1471-1484.e18.	13.5	198
25	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	13.5	270
26	Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications, 2015, 6, 7712.	5.8	258